Compare RES & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RES | NVAX |
|---|---|---|
| Founded | 1984 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oilfield Services/Equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.6B |
| IPO Year | 1995 | 1996 |
| Metric | RES | NVAX |
|---|---|---|
| Price | $7.61 | $8.11 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 5 | 9 |
| Target Price | $5.64 | ★ $11.33 |
| AVG Volume (30 Days) | 2.2M | ★ 3.1M |
| Earning Date | 05-05-2026 | 05-08-2026 |
| Dividend Yield | ★ 2.15% | N/A |
| EPS Growth | N/A | ★ 309.76 |
| EPS | 0.15 | ★ 2.58 |
| Revenue | ★ $41,919,000,000.00 | $1,123,479,000.00 |
| Revenue This Year | $3.29 | N/A |
| Revenue Next Year | $4.05 | N/A |
| P/E Ratio | $49.77 | ★ $3.27 |
| Revenue Growth | ★ 2216.21 | 64.69 |
| 52 Week Low | $4.18 | $5.80 |
| 52 Week High | $7.53 | $11.85 |
| Indicator | RES | NVAX |
|---|---|---|
| Relative Strength Index (RSI) | 63.68 | 40.20 |
| Support Level | $5.19 | $8.01 |
| Resistance Level | N/A | $8.45 |
| Average True Range (ATR) | 0.30 | 0.35 |
| MACD | 0.05 | 0.04 |
| Stochastic Oscillator | 79.22 | 29.30 |
RPC Inc is an oilfield services company. It provides specialized oilfield services and equipment to independent and oil and gas companies engaged in the exploration, production, and development of oil and gas properties throughout the United States. Its operating segment includes Technical Services and Support Services. The Technical Services segment, which generates maximum revenue, comprises service lines that generate revenue based on equipment, personnel, or materials at the well site and are closely aligned with completion and production activities of the customers. The Support Services segment comprises service lines that generate revenue from services and equipment offered off the well site and are closely aligned with the customers' drilling activities.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.